Type
Internal restructuring
Country
France
Region
Location of affected unit(s)
Lyon, Saint-Priest, Saint-Vulbas, Toulouse
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.20 - Manufacture of pharmaceutical preparations

146 - 149 jobs
Number of planned job losses
Job loss
Announcement Date
4 November 2025
Employment effect (start)
4 November 2025
Foreseen end date

Description

Boehringer Ingelheim, the German pharmaceutical company has announced a reorganisation of its activities in France. There will be 149 jobs losses and 58 contracts modified.

The measures will primarily affect the Lyon headquarters, where around 70 positions are set to be eliminated, but it will also impact other three R&D and production sites: the Saint-Priest site near Lyon, is expected to lose around 60 positions; the remaining job cuts will happen in the Saint-Vulbas R&D centre and the Toulouse production site.

The company has justified the transformation by the need to strengthen its competitiveness in the animal health sector, despite reporting strong financial results in 2024. Trade union Force Ouvrière has publicly denounced the project, opposing any dismissals and accusing management of dismantling the company without transparency

Previously in the ERM Events database, Boehringer Ingelheim was involved in another restructuring involving between 327 and 507 job losses in 2019 Boehringer Ingelheim France 2019 - FR


Sources

Citation

Eurofound (2025), Boehringer Ingelheim France, Internal restructuring in France, factsheet number 203673, European Restructuring Monitor. Dublin, https://dev.eurofound.europa.eu/restructuring-events/detail/203673.